Table 1.
Baseline demographics and disease characteristics (efficacy populations)
| First year of study | Second year of study | |||
|---|---|---|---|---|
| Receiving alendronate (n = 124) | Receiving denosumab (n = 126) | Receiving alendronate (n = 115) | Receiving denosumab (n = 106) | |
| Sex, female, n (%) | 124 (100) | 126 (100) | 115 (100) | 106 (100) |
| Ethnicity/race, n (%) | ||||
| White or Caucasian | 119 (96.0) | 115 (91.3) | 107 (93.0) | 102 (96.2) |
| Hispanic or Latino | 1 (0.8) | 6 (4.8) | 4 (3.5) | 1 (0.9) |
| Black or African American | 2 (1.6) | 2 (1.6) | 1 (0.9) | 1 (0.9) |
| Other | 2 (1.6) | 3 (2.4) | 3 (2.6) | 2 (1.9) |
| Age, years, mean (SD) | 65.3 (7.7) | 65.1 (7.6) | 65.1 (7.4) | 65.3 (7.4) |
| Years since menopause, mean (SD) | 17.2 (10.0) | 18.2 (11.4) | 17.9 (10.9) | 17.0 (9.7) |
| BMD T-scores at year baseline, mean (SD) | ||||
| Lumbar spine | −1.89 (1.13) | −2.04 (1.16) | −1.61 (1.29) | −1.44 (1.15) |
| Total hip | −1.60 (0.76) | −1.60 (0.74) | −1.38 (0.74) | −1.40 (0.73) |
| Femoral neck | −2.03 (0.62) | −2.01 (0.55) | −1.84 (0.60) | −1.90 (0.63) |
Values are given for baseline (start of the first year)
SD standard deviation, BMD bone mineral density